141 related articles for article (PubMed ID: 8336941)
1. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
[TBL] [Abstract][Full Text] [Related]
2. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element.
Zhang W; Guo XY; Deisseroth AB
Oncogene; 1994 Sep; 9(9):2513-21. PubMed ID: 8058314
[TBL] [Abstract][Full Text] [Related]
3. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
Zhang W; Shay JW; Deisseroth A
Cancer Res; 1993 Oct; 53(20):4772-5. PubMed ID: 8402659
[TBL] [Abstract][Full Text] [Related]
4. Novel DNA binding of p53 mutants and their role in transcriptional activation.
Zhang W; Funk WD; Wright WE; Shay JW; Deisseroth AB
Oncogene; 1993 Sep; 8(9):2555-9. PubMed ID: 8361764
[TBL] [Abstract][Full Text] [Related]
5. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
6. Distinct regions of p53 have a differential role in transcriptional activation and repression functions.
Sang BC; Chen JY; Minna J; Barbosa MS
Oncogene; 1994 Mar; 9(3):853-9. PubMed ID: 8108128
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
9. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
10. p53 transactivation through various p53-responsive elements.
Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
[TBL] [Abstract][Full Text] [Related]
11. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
13. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
14. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells.
Prasad KA; Church JG
Biochem Biophys Res Commun; 1997 Mar; 232(1):14-9. PubMed ID: 9125118
[TBL] [Abstract][Full Text] [Related]
16. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
Abarzúa P; LoSardo JE; Gubler ML; Neri A
Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
[TBL] [Abstract][Full Text] [Related]
17. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
18. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
[TBL] [Abstract][Full Text] [Related]
19. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
20. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
